Breed · Dog

Miniature Poodle: adverse event reports

FDA breed label "Poodle - Miniature" · single-breed animals only

Read this first · FDA's caveat, in its words

An API dataset query result cannot be used to estimate the risk associated with the product or compare one drug or device product with another. When looking at the results, be aware that there is no certainty that the reported drug or device caused the adverse event. This dataset should not be the sole source of information for clinical decision-making or other assumptions about the safety or effectiveness of a product. The adverse event may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources. FDA Center for Veterinary Medicine

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

Not veterinary advice. This site lists what was reported to FDA. For an animal that is unwell, contact a veterinarian.

4,365reports, 2003–20260.4% of dog reports

253reports, 12 months to March 2026262 in the 12 months before

40.2%classed serious, as reportedall dogs: 38.3%

14.4%name milbemycin oxime + spinosadall dogs: 13.1%

4,365 adverse event reports received by FDA describe an animal recorded as Miniature Poodle (FDA breed label "Poodle - Miniature"). That is 0.4% of all reports about dogs. Crossbred animals are not counted here, only reports that give this single breed.

253 reports arrived in the 12 months to March 2026, close to the 262 of the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.

By active ingredient, the drugs named most often are milbemycin oxime + spinosad, ivermectin + pyrantel pamoate and afoxolaner. Milbemycin Oxime + Spinosad is named in 14.4% of this breed's reports, about the same share as in reports about all dogs (13.1%).

The terms listed most often are vomiting (24.5%), lethargy (13.2%) and emesis (9.8%). Vomiting appears in 24.5% of reports, about the same share as in all dog reports (19.7%). 40.2% of reports stating seriousness were classed as serious, against 38.3% for dogs overall.

Drugs named most often, by active ingredient

Active ingredients recorded for the drug	Reports	Share of Miniature Poodle reports	Share of all dog reports
Milbemycin Oxime + Spinosad	629	14.4%	13.1%
Ivermectin + Pyrantel Pamoate	573	13.1%	14.9%
Afoxolaner	469	10.7%	5.7%
Fluralaner	435	10%	6.7%
Spinosad	216	4.9%	5.8%
Pyrantel Pamoate + Sarolaner	213	4.9%	5.1%
Lufenuron + Milbemycin Oxime	162	3.7%	2.7%
Trilostane	156	3.6%	1.2%
Imidacloprid + Moxidectin	143	3.3%	1.3%
Moxidectin	134	3.1%	5%
Oclacitinib	113	2.6%	2.9%
Milbemycin Oxime + Praziquantel	108	2.5%	3.1%
Insulin	104	2.4%	0.7%
Sarolaner	76	1.7%	1.7%
Maropitant	70	1.6%	1.2%
Pimobendan	70	1.6%	0.6%
Febantel + Praziquantel + Pyrantel Pamoate	65	1.5%	0.7%
Nitenpyram	62	1.4%	1.1%
Carprofen	54	1.2%	4.8%
Bedinvetmab	53	1.2%	1.9%

Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.

Signs listed in reports

share of Miniature Poodle reports listing the termall dog reports

Vomiting24.5%1,068
Lethargy[unusually tired or inactive]13.2%574
Emesis[vomiting]9.8%427
Diarrhoea[diarrhea]8.9%388
Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]6.3%274
Seizure NOS[seizure, type not specified]5.2%228
Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]4.4%190
Anorexia[not eating]4.3%189
Lack of efficacy - NOS[the product did not have the expected effect]4.1%177
Emesis (multiple)[vomiting more than once]3.3%142
Behavioural disorder NOS[behaviour change, type not specified]3%133
Decreased appetite2.8%121
Not eating2.7%119
Other abnormal test result NOS[abnormal laboratory result, type not specified]2.7%116
Ataxia[unsteady, uncoordinated movement]2.5%107
Overdose[more than the labelled amount was given]2.2%98
Digestive tract disorder NOS[digestive problem, type not specified]2.2%96
Pruritus[itching]2.1%91
Shaking2.1%90
Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]2%89
Bloody diarrhoea[diarrhea with blood]1.8%79
Death1.7%76
Death by euthanasia[the animal was euthanized]1.7%75
Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]1.7%75
Ineffective, hooks[legacy FDA term: the product did not have the expected effect (hooks)]1.7%73

Age and weight

Age of the animal

Under 1 year9.7%425

1 to 3 years22.5%984

4 to 7 years23.6%1,030

8 to 11 years21.6%941

12 years and over18.8%821

Age not given3.8%164

Weight of the animal

Under 5 kg (11 lb)36.2%1,581

5 to 9.9 kg (11–22 lb)52.6%2,296

10 to 24.9 kg (22–55 lb)8%351

25 to 44.9 kg (55–99 lb)0.4%19

45 kg and over (99 lb+)0%0

Weight not given2.7%118

Coloured bar: Miniature Poodle reports. Grey bar: all dog reports.

Trend and outcomes

Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcome recorded in the report

Recovered/Normal40%1,744

Recovered with Sequela3%129

Ongoing21.4%934

Died1.9%83

Euthanized1.7%75

Outcome Unknown32%1,398

Beside all dogs

Measure	Miniature Poodle	All dogs
Reports	4,365	985,675
Latest 12 months	253	53,292
Classed serious, of reports stating it	40.2%	38.3%
Death or euthanasia recorded, per 1,000 reports	36.2	55

Questions about Miniature Poodle reports

How many FDA adverse event reports involve Miniature Poodles?

4,365 reports through March 2026, 0.4% of reports about dogs; 253 in the latest 12 months.

Which drugs are named most often in Miniature Poodle reports?

By active ingredient: milbemycin oxime + spinosad (629), ivermectin + pyrantel pamoate (573), afoxolaner (469), fluralaner (435) and spinosad (216). Brands are masked in the public data.

What signs are reported most for this breed?

vomiting (24.5%), lethargy (13.2%), emesis (9.8%), diarrhoea (8.9%) and lack of efficacy (ectoparasite) - flea (6.3%).

Is the Miniature Poodle more sensitive to certain drugs?

Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Miniature Poodle animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.

Why are crossbreds not included?

FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Poodle - Miniature" becomes "Miniature Poodle"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.